Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

251 results about "Tumor microenvironment" patented technology

The tumor microenvironment (TME) is the environment around a tumor, including the surrounding blood vessels, immune cells, fibroblasts, signaling molecules and the extracellular matrix (ECM). The tumor and the surrounding microenvironment are closely related and interact constantly. Tumors can influence the microenvironment by releasing extracellular signals, promoting tumor angiogenesis and inducing peripheral immune tolerance, while the immune cells in the microenvironment can affect the growth and evolution of cancerous cells.

Gold nanocage-manganese dioxide composite nanoparticle as well as preparation method and application thereof

ActiveCN107670040AImprove hypoxic microenvironmentGive full play to the photodynamic effectPhotodynamic therapyGeneral/multifunctional contrast agentsTumor targetManganese
The invention discloses a gold nanocage-manganese dioxide composite nanoparticle as well as a preparation method and application thereof, and relates to the technical field of nanoparticle photodynamic therapy. The composite nanoparticle comprises a gold nanocage inner core and a manganese dioxide shell layer. The preparation method is characterized in that potassium permanganate is reduced by a one-step reduction method; the manganese dioxide shell layer covers the surface of the gold nanocage, wherein the gold nanocage inner core achieves a photodynamic curative effect under the triggering of near-infrared light; the manganese dioxide shell layer is degraded in tumor microenvironment and releases oxygen, so that the tumor oxygen deficiency is relieved, and the photodynamic curative effect is enhanced; on the other hand, the opto-acoustic and magnetic resonance bimodule imaging can also be realized. The problem of insufficient photodynamic curative effect caused by factors such as tumor oxygen deficiency and photodynamic oxygen consumption of a nanometer photosensitizer used in the prior art is solved. The photodynamic curative effect of the gold nanocage-manganese dioxide composite nanoparticle is obvious; the gold nanocage-manganese dioxide composite nanoparticle can be applied to tumor targeted oxygenation photodynamic diagnosis and treatment integration.
Owner:SHENZHEN INST OF ADVANCED TECH

Preparation and characterization method of photosensitizer/antitumor drug self-assembled nano drug delivery system based on hyaluronic acid

The invention belongs to the field of organic synthesis or pharmaceutical preparations and relates to a synthesis method of a hyaluronic acid-photosensitizer/antitumor drug with synergistic anti-tumor efficacy and a preparation method of a nano drug delivery system. Conjugates are amphiphilic by connecting a photosensitizer and an indissolvable antitumor drug on a hyaluronic acid skeleton by ester bonds and are self-assembled in water to obtain a nanomicelle. The synthesis method and the preparation method are characterized by comprising the synthesis method of covalent linkage of hyaluronic acid and a photosensitizer/antitumor drug and a method for self-assembling the nano drug delivery system by the hyaluronic acid-photosensitizer/antitumor drug. The system is expected to have good biocompatibility and active targeting property of tumors in a body; the solubility of the indissolvable antitumor drug can be improved, the phagocytosis of a reticuloendothelial system is avoided, and the cycle time in the body is prolonged; after the system reaches a lesion location, the ester bonds of the system are fractured in a tumor microenvironment under the condition of a low pH value and releases the photosensitizer and the antitumor drug; the system is excited by near-infrared light to generate heat and fluorescence; on one hand, tumor cells are killed and wounded by a phototherapy and chemotherapy combined mode; on the other hand, distribution conditions of the tumor cells in the body can be characterized.
Owner:CHINA PHARM UNIV

Nanogel and nanogel drug carrier system both with smart response to tumor microenvironment

ActiveCN106810636AHas pHHas GSH dual responsivenessOrganic active ingredientsAerosol deliveryLysosomePh regulation
The invention provides a nanogel with hydrophilic and hydrophobic reversal, charge reversal and intracellular redox responsiveness on the basis of pH regulation. The nanogel is prepared by cross-linking of thermo-sensitive monomer with controllable radical polymerization, amphoteric ionic monomer and amido-containing pH sensitive monomer through a disulfide-bond-containing cross-linking agent. The invention further provides a nanogel drug carrier system with smart response to tumor microenvironment and its preparation method. On the condition of blood pH 7.4, the nanogel is in a hydrophilic swelling state that is favorable for avoiding being phagocytosed by the reticuloendothelial system (RES) and accordingly, the nanogel has blood long circulation capacity; on the condition of tumor tissue subacidity, the state of the nanogel is reversed into a hydrophobic shrinking state that is favorable for the nanogel to realize effective concentration, depth penetration and be absorbed effectively by tumor cells on the tumor location. Besides, in the intracellular lysosome environment, negative charge of the nanogel is reversed into positive charge, which is favorable for the nanogel to escape from the lysosome; and then the nanogel releases drugs responsively in cytoplasm high-GSH environment, thereby achieving a good tumor inhibition effect.
Owner:HUAZHONG UNIV OF SCI & TECH

Internally and externally refined composite nano photosensitizer as well as preparation method and application thereof

The invention discloses an internally and externally refined composite nano photosensitizer as well as a preparation method and application thereof and belongs to the technical field of nanometer biomedicine. The preparation method disclosed by the invention comprises the following steps: removing a surface ligand from rare-earth upconversion nanoparticles, and modifying by a photosensitizer to obtain an upconversion nano photosensitizer; and coating luminescence molecules and the upconversion nano photosensitizer by virtue of hydrophobic-hydrophobic interactions by adopting amphiphilic polymers, thereby obtaining the composite nano photosensitizer. The composite nano photosensitizer is capable of simultaneously responding to stimulus of a tumor microenvironment so as to realize internal photodynamic force and external photodynamic force under near-infrared light excitation. By combining the characteristic that hydrogen peroxide and the like is highly expressed in the tumor microenvironment with the characteristic of upconversion emission of near-infrared light excitation, tumors are inhibited in both modes in an internally and externally refined manner. After a covalent or chemical coordination manner on the surface of the rare-earth upconversion nanoparticles is combined with the photosensitizer, the energy transfer efficiency can be improved, the singlet oxygen yield is increased, and the photodynamics therapy effect under external excitation can be effectively improved.
Owner:CHANGCHUN INST OF OPTICS FINE MECHANICS & PHYSICS CHINESE ACAD OF SCI

Micromolecular conjugate based on RGD polypeptide-chemotherapy drug and nanometer prodrug system thereof

The invention relates to a micromolecular conjugate based on RGD polypeptide-chemotherapy drug and a self-assembly nanometer prodrug system thereof, and belongs to the technical field of biological medicine and nanometer medicine. The nanometer prodrug system has the main advantages that (1) the system is formed by RGD polypeptide and an anti-tumor drug through direct covalent connection via micromolecular connecting arms, and the drug loading capacity of the system is improved; (2) the conjugate is self-assembled into a nanometer prodrug using the drug as a hydrophobic inner core and the RGD polypeptide as a hydrophilic outer shell, the active targeting on tumor cells and tumor new vessels is realized through the ligand-receptor mutual action, and the endocytosis is promoted; (3) the stability of the nanometer prodrug system in the body circulation can be ensured through thioether bonds, reduction sensitive bonds and cathepsin B sensitive bonds, and the cytotoxic drug is released when the nanometer prodrug system reaches the tumor microenvironment; and (4) the micromolecular conjugate instead of a macromolecular material is used as a carrier, so that the nanometer prodrug system can favorably and better penetrate into the tumor tissues and cells to achieve better anti-tumor effects.
Owner:PEKING UNIV

Transgenic T cell of targeted CD30 antigen as well as preparation method and application of transgenic T cell

The invention discloses a transgenic T cell of a targeted CD30 antigen. The transgenic T cell is a primary cell which is integrated with a gene shown as SEQ ID NO:2 and encoding the targeted CD30 antigen, and knocks out a PD1 gene and / or CTLA4 gene, or is a primary cell containing a recombinant lentivirus expression vector (including a gene which is shown as SEQ ID NO:2 and encodes the targeted CD30 antigen and shRNA of a targeted PD1 gene or / and shRNA of a targeted CTLA4 gene); the primary cell is CD4+T cell or CD8+T cell. A preparation method comprises the following steps: firstly, carryingout lentivirus infection on the CD4+T cell or the CD8+T cell; secondly, mixing gRNA, CRISPR-cas9mRNA and HDR, and carrying out electroporation recombination on the T cell to obtain a finished product.According to the transgenic T cell disclosed by the invention, a recognition sequence of an EGFR (Epidermal Growth Factor Receptor) is introduced in carT construction; if necessary, a carT cell can be eliminated by using EGFR monoclonal antibody Cetuximab, the PD1 gene and the CTLA4 gene are knocked out or silenced, inhibition of the gene to the carT cell is eliminated, and the function of overcoming a tumor microenvironment and inhibiting immune cells by the carT cell are enhanced.
Owner:YINFENG BIOLOGICAL GRP

Polydopamine nano diagnosis and treatment agent and preparation method thereof

The invention discloses a polydopamine nano diagnosis and treatment preparation and a preparation method thereof. The nano diagnosis and treatment agent is prepared by the following steps: taking mesoporous polydopamine as a carrier, respectively supporting rhodium nanoparticles in the hole and on the surface of the mesoporous polydopamine by virtue of a hydrothermal synthesis reaction, and adsorbing a photosensitizer dihydroporphin (Ce6) onto the polydopamine and rhodium nanoparticles, thereby obtaining the polydopamine nano diagnosis and treatment agent with excellent dispersion property. Byutilizing photothermal effects of the carrier mesoporous polydopamine and the rhodium nanoparticles, the temperature of the tumor site is locally raised. By combining with catalytic characteristics of the rhodium nanoparticles, hydrogen peroxide in a tumor microenvironment is catalyzed to decompose so as to produce oxygen, and aims of producing singlet oxygen and effectively killing cancer cellsare achieved under the conditions of the photosensitizer Ce6 and applied laser. Meanwhile, by combining with photoacoustic imaging characteristics of the polydopamine, the aim of guiding photothermaltherapy and photodynamic synergistic therapy by photoacoustic imaging can be achieved, and the tumor treatment effect is expected to be improved. Moreover, the polydopamine nano diagnosis and treatment agent is excellent in biocompatibility, and has clinical application potential.
Owner:SUN YAT SEN UNIV

Tumor microenvironment response nanoparticle based on peptides dendrimer modified fluorescence carbon dots and preparation method of tumor microenvironment response nanoparticle

The invention discloses a tumor microenvironment response nanoparticle based on peptides dendrimer modified fluorescence carbon dots. A preparation method of the tumor microenvironment response nanoparticle comprises the following steps: (1) preparation of nanometer fluorescence carbon dots; (2) surface sulfhydrylation modification of the fluorescence carbon dots; (3) preparation of second-generation peptides dendrimer grafted by arginine-lysine; (4) surface modification of the second-generation peptides dendrimer with fluorescence carbon dots; (5) preparation of a zwitterionic polymer polycarboxylate betaine methacrylate; (6) preparation of drug-loading carbon dots; (7) preparation of a drug-loading nanoparticle. The drug-loading nanoparticle prepared with the method has the specific fluorescent property of the carbon dots and dual high-sensitive responsiveness for an acid environment of a tumor site and high-concentration glutathione, high-selectivity rapid drug release in tumor cells can be achieved, and the drug-loading nanoparticle is high in anti-tumor efficiency and good in safety; in addition, integration of diagnosis and treatment of tumors is expected to achieve.
Owner:SICHUAN UNIV

Myeloma BCMA antigen-targeted transgenic T cell, and preparation method and application thereof

The invention discloses a gene for encoding anti-BCMA chimeric antigen receptor. The nucleotide sequence of the gene is represented by SEQ ID NO:2. The invention also discloses a recombinant expression vector containing the gene, and a myeloma BCMA antigen-targeted transgenic T cell. The transgenic T-cell is a primitive cell containing the recombinant expression vector and knocked out of a PD1 gene or/and a CTLA4 gene, or is a primitive cell with the chromosome being integrated with the gene for encoding anti-BCMA chimeric antigen receptor and knocked out of tbe PD1 gene or/and the CTLA4 gene.A preparation method of the transgenic T-cell comprises the following steps: mixing of gRNA, CRISPR-cas9 mRNA and HDR mix, and electrotransformation recombination of the T cell. The invention furtherdiscloses an application of the myeloma BCMA antigen-targeted transgenic T cell in the preparation of drugs for treating multiple myeloma. In the construction process of carT of, a recognition sequence of EGFR is introduced, EGFR monoclonal antibody Cetuximab is used to eliminate a carT cell if necessary, and PD1 and CTLA4 genes are knocked out to relieve the inhibition effect of the PD1 and CTLA4 genes on the carT cell and enhance the overcoming effect of the carT cell on the inhibition of the tumor microenvironment on immune cell functions.
Owner:YINFENG BIOLOGICAL GRP +1

PH-sensitive targeted LPNs (lipid poly-L-histidine hybrid nanoparticles) for encapsulating anti-tumor drugs

The invention relates to PH-sensitive targeted LPNs (lipid poly-L-histidine hybrid nanoparticles) for encapsulating anti-tumor drugs. The LPNs comprise raw materials in percentage by mass as follows:50%-80% of PHIS (poly-histidine) and 20%-50% of lipid (including lipid-PEG), wherein the lipid PEG accounts for 1%-100% of the total mass of lipid. A hydrophobic core consists of PHIS, and the surfaceis modified with polyethylene glycol and tumor targeted peptide. The PEGylated lipid surface has the characteristics of good biocompatibility, high stability and long in-vivo circulation. A histidinecore can encapsulate the hydrophobic anti-cancer drugs under the neutral condition, histidine is protonized in the tumor microenvironment to mediate the carrier potential to change from negative to near neutral, intake and endocytosis of a carrier arepromoted, the carrier mediates the lysosome to escape after endocytosis, the drugs are released rapidly, tumor cells are effectively killed, and accordingly, the problems that the PEGylated nano-carrier endocytosis efficiency is low and cannot release the drugs in cells effectively after endocytosis are solved. The surface of the carrier can bemodified with a tumor-specific antibody or ligand, the tumor targeting property is further improved, and the therapeutic effect is improved.
Owner:TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products